NCT07093710

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

The Safety and Efficacy of Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma: A Prospective, Multicenter, Open-label, Phase Ib/II Clinical Study

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 101 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of golidocitinib combined with mitoxantrone hydrochloride liposome or chidamide in the treatment of relapsed or refractory peripheral T-cell lymphoma

Conditions

• Peripheral T Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Golidocitinib	150mg, po, qd;
DRUG	Mitoxantrone Hydrochloride Liposome	Cohort 1: 15 mg/m2, IV, D1 and 18 mg/m2, IV, D1 (phase Ib); RP2D (II study)
DRUG	Chidamide	Cohort 2: Chidamide：20mg/30mg, po, Biw (phase Ib); RP2D (phase II study)

Timeline

• Start date: 2025-08-27
• Primary completion: 2027-08-01
• Completion: 2029-08-01
• First posted: 2025-07-30
• Last updated: 2025-12-31

Locations

1 site across 1 country: China